Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Etidronic acid
Drug ID BADD_D00849
Description Etidronic acid is a first generation bisphosphonate similar to [clodronic acid] and [tiludronic acid].[A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.[A1923] Etidronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid].[A203111] Etidronic acid was granted FDA approval on 1 September 1977.[L13901]
Indications and Usage Etidronate is indicated to treat Paget's disease of bone, as well as the treatment and prevention of heterotropic ossification after total hip replacement of spinal cord injury.[L13901]
Marketing Status approved
ATC Code M05BA01
DrugBank ID DB01077
KEGG ID D02373
MeSH ID D012968
PubChem ID 3305
TTD Drug ID D00NNC
NDC Product Code Not Available
UNII M2F465ROXU
Synonyms Etidronic Acid | (1-hydroxyethylene)diphosphonic acid | Hydroxyethylidene Diphosphonic Acid | Diphosphonic Acid, Hydroxyethylidene | Etidronate | 1-Hydroxyethane-1,1-Diphosphonate | 1 Hydroxyethane 1,1 Diphosphonate | 1-Hydroxyethylidene-1,1-Bisphosphonate | 1 Hydroxyethylidene 1,1 Bisphosphonate | EHDP | 1,1-hydroxyethylenediphosphonate | 1,1 hydroxyethylenediphosphonate | HEDP | Hydroxyethanediphosphonate | Ethanehydroxyphosphate | Ethanehydroxydiphosphonate | Etidronate Disodium | Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt | Sodium Etidronate | Etidronate, Sodium | Disodium 1-Hydroxyethylene Diphosphonate | 1-Hydroxyethylene Diphosphonate, Disodium | Diphosphonate, Disodium 1-Hydroxyethylene | Disodium 1 Hydroxyethylene Diphosphonate | Disodium Etidronate | Etidronate, Disodium | HEDSPA | Dicalcium Etidronate | Etidronate, Dicalcium | Dicalcium EHDP | EHDP, Dicalcium | Xidifon | Xydiphone | Xidiphon | Didronel | Etidronate, Tetrapotassium Salt | Salt Etidronate, Tetrapotassium | Tetrapotassium Salt Etidronate | (1-hydroxyethylene)diphosphonic acid, Tetrapotassium Salt
Chemical Information
Molecular Formula C2H8O7P2
CAS Registry Number 2809-21-4
SMILES CC(O)(P(=O)(O)O)P(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Amnesia17.03.02.001; 19.20.01.001--
Anaemia01.03.02.001--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Bone pain15.02.01.001--
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dyspepsia07.01.02.001--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Fracture12.04.02.001; 15.08.02.001--
Gastritis07.08.02.001--
Gastrointestinal pain07.01.05.005--
Glossitis07.14.01.001--Not Available
Glossodynia07.14.02.001--Not Available
Hallucination19.10.04.003--
Headache17.14.01.001--
Hypercalcaemia of malignancy05.08.02.001; 16.32.01.001; 14.04.01.009--Not Available
Hypersensitivity10.01.03.003--
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene